Role of cancer-associated fibroblasts in the resistance to antitumor therapy, and their potential therapeutic mechanisms in non-small cell lung cancer (Review)

CONGCONG CHEN1, JIA HOU2, SIZHE YU2, WENYUAN LI2, XIAO WANG2, HONG SUN2, TIANJIE QIN2, FRANCOIS X. CLARET3, HUI GUO2,4 and ZHIYAN LIU1,5

1School of Life Science, Northwest University, Xi’an, Shaanxi 710069; 2Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi 710061, P.R. China; 3Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston TX77030, USA; 4Key Laboratory of Environment and Genes Related to Diseases, Xi’an Jiaotong University, Ministry of Education of China, Xi’an, Shaanxi 710061; 5Department of Respiratory and Critical Care Medicine, Xi’an No. 3 Hospital, The Affiliated Hospital of Northwest University, Xi’an, Shaanxi 710018, P.R. China

Received November 1, 2020; Accepted February 26, 2021

DOI: 10.3892/ol.2021.12674

Abstract. Non-small cell lung cancer (NSCLC) is a malignant tumor with high morbidity and mortality rates, which seriously endangers human health. Although treatment methods continue to evolve, the emergence of drug resistance is inevitable and seriously hinders the treatment of NSCLC. The tumor microenvironment (TME) protects tumor cells from the effects of chemotherapeutic drugs, which can lead to drug resistance. Cancer-associated fibroblasts (CAFs) are an important component of the TME, and various studies have demonstrated that CAFs play a crucial role in drug resistance in NSCLC. However, the drug resistance mechanism of CAFs and whether CAFs can be used as a target to reverse the resistance of tumor cells remain unclear. The present review discusses this issue and describes the heterogeneity of CAF markers, as well as their origins and resident organs, and the role and mechanism of this heterogeneity in NSCLC progression. Furthermore, the mechanism of CAF-mediated NSCLC resistance to chemotherapy, targeted therapy and immunotherapy is introduced, and strategies to reverse this resistance are described.

Correspondence to: Dr Zhiyan Liu, Department of Respiratory and Critical Care Medicine, Xi’an No. 3 Hospital, The Affiliated Hospital of Northwest University, 10 East Section of Fengcheng Third Road, Xi’an, Shaanxi 710018, P.R. China
E-mail: 1441999403@qq.com

Key words: cancer-associated fibroblasts, non-small cell lung cancer, resistance, mechanism, therapy strategy

Contents
1. Introduction
2. Heterogeneity of CAFs
3. Roles and mechanisms of CAFs in NSCLC drug resistance
4. Therapeutic strategies
5. Conclusions

1. Introduction

Lung cancer is a malignant disease with high morbidity and mortality rates, and non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer cases. Clinically, only a small percentage of patients with NSCLC are diagnosed at an early stage (I or II), at which tumors can be surgically removed. The majority of patients with NSCLC present with locally advanced or metastatic disease at the time of diagnosis, leaving chemotherapy, targeted therapy, and immunotherapy as the primary treatment strategies (1). However, primary resistance and acquired resistance after long-term drug usage are inevitable problems (2). Previous data suggest that the 5-year survival rate of patients with advanced NSCLC is <5% (3). Moreover, the occurrence of drug resistance is a major obstacle to successful treatment, which requires urgent medical attention (3,4).

Existing therapeutic approaches primarily counter drug resistance by targeting tumor cells and sparing those of the tumor microenvironment (TME). Since the concept of ‘seed and soil’ was proposed, the role of the TME in tumor drug resistance has received increasing attention. For example, a hypoxic microenvironment was found to induce cisplatin resistance in NSCLC (5,6). Collagen, a component of the extracellular matrix (ECM), induces NSCLC resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) by binding to the collagen receptor integrin α1β1 (7). In addition to these physical factors, stromal cells that surround the tumor, such as...
cancer stem cells (CSCs) (8) and stromal fibroblasts (9), can induce therapeutic resistance in NSCLC. Cancer-associated fibroblasts (CAFs) are an important component of the TME (10), which serve a primary role in drug resistance. Compared with tumor cells, CAFs are considered to be genetically stable with few mutations (11), and can influence tumor progression through the secretion of ECM proteins, proteases, cytokines, chemokines and growth factors (12,13). In addition, CAFs are involved in drug resistance in various malignancies, such as head and neck (14), breast (15), ovarian (13), gastrointestinal (16), pancreatic (17) and colorectal cancer (18), though the underlying mechanisms differ between tumor types. Thus, the mechanisms of CAF-mediated NSCLC resistance have gained considerable attention (19). The present review describes the functions and mechanisms of CAFs in NSCLC drug resistance, as well as potential strategies to reverse this effect.

2. Heterogeneity of CAFs

Numerous types of stromal cell, including fibroblasts, are present in the TME. Fibroblasts are activated in response to cancer cells, after which they are referred to as CAFs or myofibroblasts. CAFs are spindle-shaped cells of variable size and proliferative capacity (20,21). Moreover, CAFs exhibit high heterogeneity in terms of origin, surface markers and resident organs, which determines their functions in tumor progression. During the early stages of tumor development, CAFs play an antitumor role by promoting tissue repair. However, as the tumor progresses, CAFs promote tumor growth, metastasis and drug resistance.  

Heterogeneity of CAF origins. Studies have demonstrated that cells, including resident tissue fibroblasts, bone marrow (BM)-derived mesenchymal stromal cells (MSCs), epithelial cells, endothelial cells, CSCs, hematopoietic stem cells (HSCs), vascular smooth muscle cells (VSMCs) and pericytes may act as the predecessors of CAFs (22-30). When healthy tissue is damaged and malignancy develops, immune cells are recruited to the site of injury, and via the release of specific mediators, activate the differentiation of resident fibroblasts into CAFs (22). In this manner, human breast fibroblasts gradually differentiate into CAFs, promoting tumor progression by establishing TGF-β and stromal-derived factor autocrine signals (23). TGF-β1 is the primary factor that activates the conversion of resident fibroblasts into CAFs. Moreover, hypoxia also promotes this process via the accumulation of reactive oxygen species (ROS) and the activation of the hypoxia-inducible factor (HIF)-1α-mediated signaling pathway (24). In addition, VSMCs and pericytes can differentiate into CAFs in breast cancer (25). BM-MSCs can also differentiate into CAFs. For example, CAFs with the phenotype and functional characteristics identical to those of BM-MSCs were isolated from primary human neuroblastoma tumors (26). In colon tumors, CAFs are generated via the activation of native mesenchymal cell populations and the recruitment of BM-MSCs (27). Furthermore, mouse-induced pluripotent stem cells were treated with conditioned media to generate CSC-like cells, which are a heterogeneous population surrounded by myofibroblast-like cells. At the same time, the expression of fibroblast activation protein (FAP), alpha-smooth muscle actin (α-SMA), and other key CAF markers was significantly increased, and for the first time, CSCs were confirmed to be the key origin of CAFs in the TME (28). Studies in two different pancreatic cancer mouse models also revealed that endothelial-mesenchymal transition transforms fibroblasts into CAFs after exposure to TGF-H1 (29). Moreover, fibroblast-specific protein-1+fibroblasts can be derived from epithelial-mesenchymal transformation (EMT) in the local environment (30). McDonald et al (31) found that CAFs derived from HSCs promoted the generation of tumor blood vessels. The origins of different CAF populations are listed in Table I.

Heterogeneity of CAF markers. The expression of CAF markers can be determined by immunofluorescence and immunohistochemical staining, and quantitatively detected by western blotting. As a heterogeneous cell population, different markers can be used to identify CAFs, the most common of which are podoplanin (PDPPN), platelet-derived growth factor receptor (PDGF-R), vimentin, α-SMA and FAP. However, in isolation, none of these markers can specifically identify CAFs (32). PDPPN+ CAFs are able to promote tumor formation (33). The expression of PDPPN was detected in the CAFs of 177 patients with lung adenocarcinoma, and PDPPN+ CAFs were found only in invasive rather than non-invasive adenocarcinoma (34). The expression of PDPPN promotes platelet aggregation and contributes to cancer cell invasive-ness (34). Therefore, PDPPN+ CAFs are closely associated with the aggressiveness of various cancer types, including lung adenocarcinoma (33,34), breast cancer (35) and squamous cell carcinoma (36). PDGF-Rs can be categorized as PDGF A and PDGF B. PDGF ligands include the PDGFS (PDGF-aa, PDGF-bb, PDGF-ab, PDGF-cc and PDGF-dd), and their expression is closely related to tumor occurrence and CAFs function (37). Vimentin is involved in the formation of cytoskeletal networks, especially in mesenchymal-derived cells. Due to their strong mesenchymal phenotype, vimentin is highly expressed in all types of fibroblasts, and has therefore been widely used for the identification of CAFs (38-40). Park et al (41) demonstrated that vimentin promotes lung cancer invasion and metastasis by promoting the recruitment of CAFs. CAFs are divided into two distinct clusters, namely C1-type and C2-type CAFs. Notably, the expression of α-SMA is lower in C1-type compared with the C2-type CAFs, though C1-type CAFs inhibit the self-renewal of oral cancer cells by releasing bone morphogenetic protein 4 (42). C2-type CAFs are characterized by high expression levels of fibroblast activation protein (FAP), alpha-smooth muscle actin (α-SMA), and other key CAF markers was significantly increased, and for the first time, CSCs were confirmed to be the key origin of CAFs in the TME (28). Studies in two different pancreatic cancer mouse models also revealed that endothelial-mesenchymal transition transforms fibroblasts into CAFs after exposure to TGF-H1 (29). Moreover, fibroblast-specific protein-1+fibroblasts can be derived from epithelial-mesenchymal transformation (EMT) in the local environment (30). McDonald et al (31) found that CAFs derived from HSCs promoted the generation of tumor blood vessels. The origins of different CAF populations are listed in Table I.
treatment of cancer, such as prostate cancer and breast cancer (49). Thapsigargin (TG) is a highly toxic natural plant product; a cytotoxic TG analog was coupled to FAP-selective peptide substrates to create inactive prodrugs, and when the prodrugs were activated, they led to apoptosis of prostate and breast cancer cells, but had no obvious toxicity to host cells (49). No single marker can mark all the CAFs, and not all CAFs express all potential marker proteins. Therefore, there is still need to investigate CAFs-specific markers. In addition to the common CAFs markers, there are other less commonly used markers, such as microfibrillar-associated protein 5 (MFAP5), collagen type XI α1, tenasin-C, PDPN, integrin α1β1, neural/glial antigen, collagen 11-α1 and asporin (40). However, collagen 11-α1, MFAP5 and asporin are expressed only by CAFs, which can improve the specificity of their identification (50). Currently, a combination of markers, as well as cellular phenotype, is the most reliable method for the identification of CAFs.

**Heterogeneity of CAF resident organs.** Though CAFs lack specific markers, literature reports that CAF markers may possess organs heterogeneity, and that CAFs expressing the same marker may possess different functions in different organs. For example, in ovarian cancer, PDGF-R+ CAFs promote tumor progression by remodeling the ECM (51). However, CAFs expressing PDGF increase the levels of the Puma in myofibroblasts, which subsequently activates Bak, a pro-apoptotic protein that induce cholangiocarcinoma cell apoptosis (52). Similarly, CAFs may express different markers in different organs. PDGF-R is expressed by a variety of different CAFs; however, those originating from BM-MSCs do not express PDGF-R in breast tumors and lung metastases (53). At present, CD200 is only known to be highly expressed in CAFs derived from NSCLC and can promote the sensitivity of NSCLC to EGFR-TKIs (54). Su et al (8) demonstrated that CD10+/GPR77+CAFs continually promote p65 phosphorylation and acetylation by binding GPR77 receptor C5α, thereby promoting the self-renewal of tumor stem cells and enhancing drug resistance in patients with lung and breast cancer.

**Role of CAF heterogeneity in NSCLC.** Heterogeneity between origins, markers and resident organs determines the different functions of CAFs. Genetically engineered mouse models and clinical studies have demonstrated that at least two types of CAFs with different functions exist, namely pro-cancer CAFs (pCAFs) and antitumor CAFs (rCAFs) (55). CAFs also exhibit different functions in tumor progression. In NSCLC, the functional heterogeneity of CAFs primarily results from differences in expression markers, and there are few studies on the functional differences caused by the heterogeneity of origins. CAFs that exert pro-tumor effects include α-SMA+PDPN+, FAP+, CD34+ and CD10+/GPR77+CAFs. CAFs with antitumor properties include CD200+ and CD99+CAFs. The pro/anti-tumor effect of CAFs in NSCLC progression are summarized in Table II.

**Pro-tumor effect of CAFs.** CAFs promote tumor growth and metastasis, as well as tumor cell drug resistance. Tissue analysis revealed a high mortality rate among 220 patients with NSCLC and high α-SMA expression, indicating that α-SMA is associated with poor survival time (56). Immunohistochemical analysis of 304 patients with pTNM stage I-III NSCLC revealed that CAF-associated CD34 expression was an independent prognostic factor for stage I-III NSCLC, and that SMA+CAFs were associated with higher tumor stages and promoted tumor progression (57). The 28 patients with NSCLC were divided into two CAF subgroups, the high desmoplastic CAFs (HD-CAFs) and low desmoplastic CAFs (LD-CAFs), according to the obtained scores and classification based on desmoplasia. Compared with LD-CAFs, HD-CAFs exhibited a higher collagen matrix remodeling rate and promoted tumor invasion and growth (58). The immunohistochemical analysis of tumor samples from 536 patients with NSCLC indicated that CAFs expressing FAP-I were associated with poor patient prognosis, which has also been demonstrated in patients with pancreatic cancer. In addition, FAP+CAFs have been associated with reduced survival time (59,60). Yoshida et al (61) demonstrated that compared with the control group, lung adenocarcinoma cells co-cultured with PDPN+ CAFs possessed greater drug resistance properties. In patients with postoperative recurrence, compared with the PDPN-CAF group, the PDPN+ group showed a lower treatment response to EGFR-TKIs. These results suggest that PDPN+ CAFs are involved in primary

| First author, year | Origin of CAFs | Cancer type | (Refs.) |
|--------------------|---------------|-------------|--------|
| Foster et al, 2018; | Resident tissue fibroblasts | Breast cancer | (22,23) |
| Kojima et al, 2010 | | | |
| Borriello et al, 2017 | Marrow-derived mesenchymal stem cells | Neuroblastoma | (26) |
| Koliaraki et al, 2017 | Marrow-derived mesenchymal stem cells | Colon cancer | (27) |
| Zeisberg et al, 2007 | Endothelial cells | Pancreatic cancer | (29) |
| Nair et al, 2017 | Cancer stem cells | Breast cancer | (28) |
| McDonald et al, 2015 | Hematopoietic stem cells | Breast cancer | (31) |
| An et al, 2020 | Vascular smooth muscle cells | Breast cancer | (25) |
| An et al, 2020 | Pericytes | Breast cancer | (25) |

CAFs, cancer-associated fibroblasts.
Roles and mechanisms of CAFs in NSCLC drug resistance

CAFs influence tumor formation by promoting drug resistance, though the associated underlying mechanisms remain unclear. Clarifying these mechanisms may help to prevent the occurrence of drug resistance in NSCLC. Next, the mechanisms by which CAFs mediate the resistance of NSCLC to chemotherapy, targeted therapy and immunotherapy, are explored. Fig. 1 illustrates the mechanisms by which CAFs regulate drug resistance in NSCLC.

Roles and mechanisms of CAF-associated chemotherapeutic resistance. CAFs promote the resistance of NSCLC to chemotherapy primarily by mediating EMT (19), remodeling the ECM (7,11), maintaining the stemness of CSCs (8) and promoting metabolic reprogramming (64-66).

Anti-tumor effect of CAFs. In addition to their tumor-promoting functions, CAFs also possess antitumor properties. For example, CD200+ CAFs enhanced the sensitivity of lung cancer to gefitinib. Moreover, individuals with CD200+ CAFs exhibit longer progression-free survival after gefitinib treatment following post-surgical relapse. The binding of CD200 to its receptor CD200R1, which is expressed by immune cells, triggers an immunosuppressive response, leading to an antitumor effect (54). In addition, CD99 is a newly discovered CAF marker, the overexpression of which may inhibit tumor progression (63). However, the tumor-suppressive mechanism of CAFs remains unclear, and requires further investigation.

3. Roles and mechanisms of CAFs in NSCLC drug resistance

CAFs promote the resistance of NSCLC to chemotherapy primarily by mediating EMT (19), remodeling the ECM (7,11), maintaining the stemness of CSCs (8) and promoting metabolic reprogramming (64-66). EMT. EMT is an important developmental process that is closely associated with drug resistance (67,68). During EMT, epithelial cell markers, such as N- and E-cadherin, are down-regulated, while mesenchymal cell markers, such as vimentin and fibronectin, are upregulated. Previous studies have reported that EMT is associated with drug resistance in pancreatic (69), bladder (70), breast (71) and colorectal cancer (72). Compared with the control group, the expression of E-cadherin in the indirect CAF co-culture group was reduced, the expression of vimentin was enhanced, and migration and invasion ability were correspondingly augmented (20). Therefore, CAFs are among the factors mediating EMT. Studies have shown that CAFs regulate EMT and promote drug resistance by secreting IL-6 and hepatocyte growth factor (HGF) (73). For example, CAFs significantly increased TGF-β1-induced EMT in cancer cells by secreting IL-6, thereby contributing to cisplatin resistance in NSCLC (74). This process involves the expression of TGF-β1, and silencing TGF-β1 reverses EMT and thus increases the sensitivity of NSCLC to cisplatin (74). HGF, also known as scatter factor, is a member of the fibrinogen family that which functions to activate EMT (75). Ying et al (19) investigated the functions of HGF in the paclitaxel resistance of NSCLC by constructing a three-dimensional microfluidic chip. The high levels of HGF secreted by CAFs enhanced the phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) activation, as well as the expression of GRP78, and promoted the resistance of NSCLC to paclitaxel. CAFs were also found to induce EMT in NSCLC cells, inducing resistance to chemotherapy. Therefore, targeting CAFs may enhance the therapeutic effect of drugs towards NSCLC.

CSCs. Studies have reported the presence of white blood cells with stem cell-like properties in patients with acute myeloid leukemia, which are designated as CSCs (76,77). CSCs are a subgroup of tumor cells that exhibit strong resistance to chemotherapy (77,78), of which there are two primary underlying mechanisms. The first outlines that in a hypoxic microenvironment, CSCs remain quiescent in a non-permanent dormant state, and that chemotherapeutic drugs primarily target rapidly dividing cancer cells, allowing quiescent stem cells to survive and regenerate to form tumors at a later point in time (79). Another mechanism is the use of ATP-binding box (ABC)

Table II. Pro- and antitumor effects of CAFs in non-small cell lung cancer progression.

| First author, year | CAF markers | Samples, n | Pro/antitumor effect | (Refs.) |
|--------------------|-------------|------------|----------------------|--------|
| Alcaraz et al, 2019 | α-SMA       | 220        | Pro                  | (56)   |
| Yoshida et al, 2015; Neri et al, 2015 | Podoplanin | 177        | Pro                  | (61,62) |
| Kilvaer et al, 2015; Cohen et al, 2008 | FAP         | 536        | Pro                  | (59,60) |
| Schulze et al, 2020 | CD34        | 304        | Pro                  | (57)   |
| Su et al, 2018     | CD10+/GPR77+ | Pro        | (8)                 |
| Ishibashi et al, 2017 | CD200      | Anti       | (54)                |
| Edlund et al, 2012 | CD99        | Anti       | (63)                |

CAF, cancer-associated fibroblast; α-SMA: α-smooth muscle actin; FAP, fibroblast activation protein.
transporters to expel chemotherapeutic drugs, resulting in drug resistance (80). CAFs primarily promote NSCLC drug resistance by maintaining the stemness of CSCs, and stimulating their self-renewal. When CAFs are co-cultured with CSCs, CAF-associated insulin-like growth factor-II (IGF-II) activates the insulin-like growth factor 1 receptor (IGF1R) on CSCs, thereby activating the IGF-II/IGF1R/Nanog signaling pathway to maintain CSCs stemness, both in vivo and in vitro. In turn, CSCs promote CAF-associated IGF-II secretion via cytokines such as basic fibroblast growth factor. The IGF-II/IGF1R axis promotes the expression of Nanog in cancer cells, and blocking the IGF-II/IGF1R/Nanog pathway reduces the stemness of CSCs (12). CAFs exhibit high CD44 expression in tumor hypoxic and avascular areas, and CAF CD44 expression is significantly increased following treatment with an angiogenesis inhibitor. Through co-cultures and tumor sphere formation assays, CAFs were found to maintain the stemness of CSCs and enhance the resistance of tumor cells to anticancer drugs, properties that were not exhibited by CD44-deficient CAFs (81). In addition, CD10+/GPR77+CAFs can maintain the stemness of CSCs by secreting IL-6 and IL-8, thereby promoting drug resistance in patients with NSCLC. CAFs promote NSCLC resistance mainly through the following pathways: HGF/PI3K/AKT, IGF-II/IGF1R/Nanog, IGF-II/IGF-1R/AKT/Sox2/ABCB1 and IGF1/IGF1R/ERK/MAPK. CAFs increase TGF-β1-induced EMT in NSCLC by secreting IL-6. CAFs promote NSCLC drug resistance by regulating the hypoxic microenvironment through high expression of HIF-1α. CAFs deliver Snail to lung cancer cells through exosomes, which induce EMT in these cells and promote drug resistance. CAFs increase the stiffness of the matrix by enhancing ECM components (such as HA, fibroblasts and collagen), thereby preventing the binding of immune checkpoint inhibitors to their receptors, and prevent the infiltration and migration of immune cells, thereby promoting immune escape. In addition, ECM stiffness functions as a barrier to tumor cell drug absorption. CAF, cancer-associated fibroblast; NSCLC, non-small cell lung cancer; CSCs, cancer stem cells; IL, interleukin; HGF, hepatocyte growth factor; PI3K, phosphatidylinositol 3 kinase; AKT, protein kinase B; IGF-II, insulin-like growth factor-II; IGF1R, insulin-like growth factor 1 receptor; ABCB1, ATP-binding cassette sub-family B member 1; ERK, extracellular signal-regulated kinases; MAPK, mitogen-activated protein kinase; TGF-β1, transforming growth factor-β1; HIF-1α, hypoxia-inducible factor-1α; EMT, epithelial-mesenchymal transition; ECM, extracellular matrix; HA, hyaluronic acid.

**Figure 1. Mechanism of CAFs in NSCLC drug resistance.** CD10+/GPR77+CAFs can maintain the stemness of CSCs by secreting IL-6 and IL-8, thereby promoting drug resistance in patients with NSCLC. CAFs promote NSCLC resistance mainly through the following pathways: HGF/PI3K/AKT, IGF-II/IGF1R/Nanog, IGF-II/IGF-1R/AKT/Sox2/ABCB1 and IGF1/IGF1R/ERK/MAPK. CAFs increase TGF-β1-induced EMT in NSCLC by secreting IL-6. CAFs promote NSCLC drug resistance by regulating the hypoxic microenvironment through high expression of HIF-1α. CAFs deliver Snail to lung cancer cells through exosomes, which induce EMT in these cells and promote drug resistance. CAFs increase the stiffness of the matrix by enhancing ECM components (such as HA, fibroblasts and collagen), thereby preventing the binding of immune checkpoint inhibitors to their receptors, and prevent the infiltration and migration of immune cells, thereby promoting immune escape. In addition, ECM stiffness functions as a barrier to tumor cell drug absorption. CAF, cancer-associated fibroblast; NSCLC, non-small cell lung cancer; CSCs, cancer stem cells; IL, interleukin; HGF, hepatocyte growth factor; PI3K, phosphatidylinositol 3 kinase; AKT, protein kinase B; IGF-II, insulin-like growth factor-II; IGF1R, insulin-like growth factor 1 receptor; ABCB1, ATP-binding cassette sub-family B member 1; ERK, extracellular signal-regulated kinases; MAPK, mitogen-activated protein kinase; TGF-β1, transforming growth factor-β1; HIF-1α, hypoxia-inducible factor-1α; EMT, epithelial-mesenchymal transition; ECM, extracellular matrix; HA, hyaluronic acid.
the stiffness of interstitial collagen by expressing high levels of integrin α1, which promotes the progression of NSCLC tumors (7). NSCLC cells cultured on a semi-solid growth substrate (to simulate the stiffness of the matrix in the TME) can promote the resistance of NSCLC to chemotherapeutic drugs (83). In lung adenocarcinoma, PDMPs can physically remodel the ECM (62). Therefore, CAFs can promote NSCLC resistance to chemotherapy via ECM remodeling.

Metabolic reprogramming. Due to mitochondrial defects, cancer cell metabolism is altered, the ability to oxidize glucose to CO₂ is inhibited, and the propensity to convert glucose into lactic acid increases. These phenomena are collectively known as the Warburg effect (64,84), which is mediated by pyruvate kinase M2 (PKM2). PKM2 is upregulated in NSCLC cell lines and can promote NSCLC resistance to cisplatin (65). Under hypoxic conditions, cisplatin-resistant cells secrete exosomes containing high concentrations of PKM2, which are absorbed by cisplatin-sensitive cells. Exosomal PKM2 also regulates glycolysis in treatment-sensitive cells, promoting cell survival and inhibiting apoptosis. Second, in the tumor microenvironment, exosomes secreted by the cisplatin-resistant cells deliver PKM2 to CAFs, and the metabolically reprogrammed CAFs release pyruvate and lactate, promoting chemotherapeutic resistance (66). In addition, CAF autophagy releases lactic acid, ketone bodies and glutamine to create a nutrient-rich microenvironment that supports tumor growth (64).

Roles and mechanisms of CAFs in the resistance to targeted therapy. CAFs mainly promote tumor EMT (85-92) and create a hypoxic microenvironment (93-96) to render NSCLC cells resistant to targeted therapy.

EMT. EMT is a reversible process regulated by several EMT-related transcription factors (EMT-TFs), such as Snail, Slug, Twist and zinc finger E-box-binding homeobox 1 (ZEB1). EMT enhances the migration and invasiveness, as well as the resistance of cancer cells to targeted therapy (85). For example, the A549 lung cancer cell line developed drug resistance after long-term treatment with gefitinib. These gefitinib-resistant cells showed reduced expression of E-cadherin and vimentin, indicating the occurrence of EMT (86). Moreover, the expression of the EMT regulator ZEB1 was increased in the HCC4006ER erlotinib-resistant cell line. HCC4006ER cells acquired an EMT phenotype and were able to activate the IGF-II/IGF-1R/AKT/Sox2/ABCB1 pathway and binding to the membrane receptor IGF-1R, in addition to activating the IGF-1R signaling pathway, small interfering (si)RNAs targeting IGF1R reversed the EMT phenotype and resistance to EGFR-TKIs (90). Choe et al (91) reported that co-culturing CAFs with NSCLC stimulated CAFs to induce EMT by activating the Hh signaling pathway, making PC9 cells resistant to erlotinib. A combination of the cell surface molecules Patched and Smoothened with the ligands sonic hedgehog, Indian hedgehog and desert hedgehog activates the transcription factor GLI1, thereby activating the Hh pathway and mediating tumor cell resistance to EGFR-TKIs by inducing EMT (92). In summary, CAFs can promote NSCLC resistance to targeted therapy by regulating EMT-TFs, and by activating multiple pathways, which also indicates that CAFs play an important role in the resistance of NSCLC to targeted therapy.

Hypoxic microenvironment. Hypoxia is a hallmark feature of the TME, and is considered to be one of the key factors for drug resistance in tumors (97). Cancer cells are often in a state of hypoxia that promotes tumor growth (98). In rapidly growing tumors, the distance between cells and blood vessels increases, which in turn impedes drug absorption into the tumor, especially in a hypoxic environment (99). For example, EGFR-mutated NSCLC cell lines exposed to high concentrations of gefitinib under low oxygen conditions acquired drug-resistant cells, known as gefitinib-resistant persistent cells (GRPs). Moreover, stem cell-associated genes are highly expressed in GRPs. This process is primarily mediated by an upregulation in IGF1 expression by HIF1, which in turn activates IGF1R on GRPs, thereby promoting NSCLC resistance to gefitinib and increasing CSCs numbers (93). The expression level of HIF-1α is upregulated in CAFs (94), indicating that these cells may promote NSCLC drug resistance by regulating the hypoxic microenvironment. In addition, HIF-1α can promote NSCLC drug resistance by inducing the expression of ABC transporters (99). EBC-1R is an NSCLC cell line resistant to the EMT inhibitors PHA-665752 and crizotinib, which possesses the characteristics of CSCs, and forms spheres (95) in which the expression of ATP-binding cassette sub-family B member 1 (ABCB1) is upregulated. Drug resistance is reversed following treatment with the ABCB1 inhibitor elacridar (95). IGF-II is an insulin-like hormone that plays an important role in regulating cellular proliferation, differentiation, senescence and drug resistance. CAFs regulate NSCLC cell drug resistance by secreting IGF-II and binding to the membrane receptor IGF-1R, in addition to activating the IGF-II/IGF-1R/AKT/Sox2/ABCB1 pathway in cancer cells, which in turn upregulates the expression of P-glycoprotein (96).

Roles and mechanisms of CAFs in immunotherapeutic resistance. Over the past few years, immune checkpoint inhibitors have played an important role in clinical trials, and have been approved as the standard therapy for advanced NSCLC (100). For instance, nivolumab and pembrolizumab targeting programmed cell death protein 1 (PD-1), atezolizumab targeting programmed cell death ligand 1 (PD-L1), and tremelimumab targeting cytotoxic T-lymphocyte antigen 4 have been approved by the United States Food and Drug Administration for NSCLC treatment (101). However, only 15-25% of patients with NSCLC respond to immune checkpoint
inhibitors, the majority of which experience primary drug resistance (102). At present, only a limited number of studies have reported CAF-mediated NSCLC resistance to immune checkpoint inhibitors, although this has also been reported for other tumor species. In NSCLC, CAFs primarily prevent the infiltration and migration of immune cells by remodeling the ECM and preventing the binding of immune checkpoint inhibitors to their receptors, thus prompting immune escape. The density and direction of the ECM influence the behavior and migration of T cells in human lung cancer. T cells generally accumulate in areas with loose stromal fibers (103), and a dense ECM serves as a contact barrier between T cells and the tumor cells (104). It also prevents T cells from binding PD-1 inhibitors, and thus promotes the resistance of tumor cells to immune checkpoint inhibitors (103). The ECM includes collagen, laminin and fibronectin. Lysyl oxidase crosslinks collagen molecules into fibers to form a dense ECM, which inhibits the migration of T cells and reduces the effect of PD-1 inhibitors (104). In a xenograft model of NSCLC, CAFs overexpressing lysyl oxidase-like-1 were found to remodel the collagen matrix in vivo (105), suggesting that CAFs promote NSCLC resistance to immunotherapeutic drugs through the ECM. CAFs are the primary producers of TGF-β (106) and can influence T cell infiltration via TGF-β. TGF-β signaling was demonstrated to inhibit T cell infiltration in breast mouse tumor models (104). CAFs specifically inhibit CD8+ T cell infiltration, thereby promoting tumor resistance to different immunosuppressive agents (107). In addition, CAFs can function as antigen-presenting cells and induce T-cell death in an antigen-dependent manner via PD-L2 and FASL (108). Compared with patients with PD-L1-CAFs, those with PD-L1+ CAFs exhibited significantly prolonged relapse-free survival, and the expression of PD-L1 in CAFs was affected by IFN-γ (109). At present, literature reporting the correlation between CAFs and immune checkpoint inhibitors is limited. The correlation between CAF-associated surface markers and immune markers was studied in 536 patients with NSCLC, and the results indicated that CAFs had little effect on immune cell infiltration in NSCLC (110). Therefore, whether CAFs also promote the drug resistance of tumor cells by inhibiting T cell infiltration requires investigated further.

### Table III. Strategies to reverse non-small cell lung cancer drug resistance.

| First author, year | Factor | Mechanisms | Resistant to | Inhibitor of | (Refs.) |
|--------------------|--------|------------|--------------|--------------|-------|
| Shien et al, 2017  | IL-6   | OSMRs/JAK1/STAT3 | Chemotherapy | JAK1 | (119) |
| Rotow et al, 2017  | HGF    | HGF/ERK | Targeted therapy | HGF | (2) |
| Tao et al, 2016    | IL-11  | IL-11R/STAT3 | Chemotherapy | STAT3 | (118) |
| Zhang et al, 2018  | IGF    | IGF1R/AKT/Sox2/P-GP | Chemotherapy | IGF2 | (96) |
| Wang et al, 2019   | ANXA3  | ANXA3/JNK | Chemotherapy | JNK | (116) |
| Wei et al, 2020    | GGT5   | Chemotherapy | Chemotherapy/immunotherapy | GGT5 | (117) |
| Najafi et al, 2019; Rebelo et al, 2018 | MMPs | Degradation of the ECM | | | (82,121) |

OSMRs, oncostatin-M; JAK1, Janus kinase1; STAT3, signal transducer and activator of transcription 3; HGF, hepatocyte growth factor; IGF, insulin-like growth factor; IGF1R, insulin-like growth factor receptor-1; P-GP, P-glycoprotein; ANXA3, Annexin A3; GGT5, γ-glutamyl transferase 5; MMP, matrix metalloproteinase; ECM, extracellular matrix.

### 4. Therapeutic strategies

The strategy for reversing NSCLC drug resistance is displayed in Table III.

**Targeting CAFs.** There are currently two available strategies for reversing drug resistance by targeting CAFs, one of which is to inhibit the production of CAFs, while the other is to block the pathways downstream of them.

Fibroblast to CAFs transformation relies on the expression of TGF-β. Treatment with TGF-β rapidly activates the TGF-β signaling pathway, resulting in the transformation of fibroblasts into myofibroblast phenotype. Myofibroblast transdifferentiation requires the production of ROS, and the expression of NAD(P)H Oxidase-4 (NOX4) is associated with the CAF marker α-SMA. A NOX4 inhibitor (GKT137831) or targeted NOX4-knockout (short hairpin RNA and siRNA) reduced the accumulation of CAFs. Therefore, CAF generation can be inhibited by decreasing NOX4 expression, which may reduce the occurrence of NSCLC drug resistance (111). Pirfenidone is a pyridine compound that inhibits fibroblast proliferation and CAF differentiation and activation (112). FAP is expressed by the majority of CAFs, and T cells can be genetically modified to express FAP-specific chimeric antigen receptors. These FAP-specific T cells recognize and destroy FAP+CAFs with subsequent antitumor effects (113). Some CAFs possess myofibroblast characteristics and express α-SMA, which can significantly promote NSCLC resistance to chemotherapy via the expression of high levels of inflammatory cytokines and chemokines (114). Plasminogen activator inhibitor-1 (PAI-1) can promote the MF characteristics of CAFs, and the expression of PAI-1 in CAFs is correlated with the expression of α-SMA (114). PAI-1 inhibitors also decrease the expression levels of α-SMA and inhibit the MF characteristics of CAFs, improving chemotherapeutic efficacy in NSCLC (114). Thus inhibiting the MF properties of CAFs may be a novel therapeutic strategy for the treatment of chemotherapy-resistant NSCLC (114).

Currently, the primary methods of reversing NSCLC drug resistance are via the inhibition CAF downstream pathways. According to literature, resistance can be reversed by...
targeted inhibition of the cytokines secreted by CAFs, such as IL-6 (115), IGFII (96), HGF (2), Annexin A3 (ANXA3) (116) and γ-glutamyl transpeptidase 5 (GGT5) (117). CAFs express IL-6 to upregulate Bcl-2 and Mcl-1, reduce the sensitivity of NSCLC to cisplatin, and protect NSCLC cells from apoptosis (115). A combination of IL-6-targeted inhibitors and cisplatin can either reduce or inhibit the cisplatin resistance in NSCLC (115). CAFs regulate NSCLC cell drug resistance through the secretion of IGF2 and by binding IGF-1R, activating the AKT/Sox2/P-GP pathway in cancer cells. Traditional chemotherapeutic regimes, combined with IGF2-targeted inhibitors, may serve as an innovative therapeutic strategy for NSCLC (96). CAFs activate ERK by secreting HGF, which contributes to the resistance of NSCLC cells to EGFR-TKIs, and combination therapy with HGF-targeted drugs restores the sensitivity of cancer cells to EGFR-TKIs (2). In addition, the expression of ANXA3 is higher in CAFs than in normal fibroblasts (NFs). Furthermore, the overexpression of ANXA3 increased the cisplatin resistance of lung cancer cells. The underlying mechanism was that CAFs enhanced chemotherapeutic resistance by activating the ANXA3/JNK signaling pathway to inhibit cisplatin-induced apoptosis. The resistance of cancer cells to cisplatin can also be decelerated using JNK-targeting inhibitors (116). GGT5 is a member of the γ-glutamyl transpeptidase family that is abundantly expressed by CAFs, promoting NSCLC resistance to paclitaxel and cisplatin. NSCLC regains its sensitivity to chemotherapy drugs when GGT5 is blocked (117). Furthermore, CAFs secrete IL-11, which activates the IL-11R/STAT3 anti-apoptotic signaling pathway by binding to IL-11R, thereby promoting the chemotherapeutic resistance of NSCLC. STAT3 inhibitors can obstruct this process and reverse drug resistance (118). With further understanding of the roles of CAFs in NSCLC drug resistance, targeted inhibition of CAFs and their secreted cytokines can serve as suitable candidates for the treatment of drug resistance.

**Targeting EMT.** CAFs secrete several types of cytokines, such as Snail and IL-6, to remodel the EMT (73,88). The secretion of IL-6 by CAFs induces EMT and promotes cisplatin resistance in NSCLC cells (73). Co-culturing of NSCLC with CAFs results in the secretion of IL-6 and oncostatin-M (OSM) from CAFs, which in turn activates STAT3. The activated OSM receptors (OSMR)/JAK1/STAT3 pathway contributes to NSCLC cell resistance to chemotherapy drugs. However, this process can be effectively blocked by the JAK1 inhibitor filgotinib (119). In addition, CAFs deliver Snail to cancer cells through exosomes to induce cancer cell EMT. However, CAFs can also inhibit EMT when treated with the exosome release inhibitor GW4869, restoring NSCLC drug sensitivity (88). CAFs also promote EMT by secreting TGF-β, indicating that the ability of the TEM to support tumor cells can be reduced by inhibiting TGF-β (120).

**Targeting the ECM.** According to the aforementioned findings, T cell migration, and the efficacy of anti-PD-1 blockers, can be improved by reducing ECM content and matrix stiffness, which can improve the sensitivity of NSCLC cells to chemotherapy and immunotherapy. Matrix metalloproteinases (MMPs), ERK1/2, JNK, and HIF-1 have been proven to promote ECM degradation (82). However, CAFs primarily degrade the ECM by secreting MMPs, and CAFs co-cultured with NSCLC cells promote the expression of MMP1 and MMP9 (121), effectively reversing drug resistance.

**Targeting CSCs.** CAFs can facilitate CSC-induced drug resistance in NSCLC in various ways. Therefore, targeting CSCs can improve the therapeutic effect on tumors. For example, CD10+/GPR77+CAF can promote the self-renewal of CSCs and enhance drug resistance in patients with lung cancer. According to these findings, GPR77 monoclonal antibody therapy may destroy the ecological niche of CSCs, thus retarding the formation of tumors and reversing chemotherapeutic resistance (8). In addition, as aforementioned, CAFs maintain the stemness of CSCs and promote NSCLC drug resistance through the IGF-II/IGF1R/Akt/Nanog signaling pathway. However, the inhibition of this pathway reverses drug resistance to NSCLC (12).

### 5. Conclusions

CAFs can promote NSCLC drug resistance by inducing EMT, increasing CSC stiffness, remodeling the ECM, and creating a hypoxic microenvironment. These functions are crucial for the role of CAFs in NSCLC drug resistance. The heterogeneity of CAFs is an important factor in the failure of cancer treatment. The lack of reliable markers to identify CAF cell populations has further hindered our understanding of the relationship between CAFs and therapeutic resistance. Therefore, identifying CAF-specific surface markers is key for the future direction of this research field. Due to the heterogeneity of CAFs, targeted inhibitors have yet to be discovered. However, drug resistance can be reversed by reducing the accumulation of CAFs, as well as targeted inhibition of their downstream pathways. In addition, the drug sensitivity of NSCLC can be restored by inhibiting EMT, degrading the ECM and destroying the ecological niche of CSCs.

### Acknowledgements

Not applicable.

### Funding

No funding was received.

### Availability of data and materials

Not applicable.

### Authors' contributions

CC was involved in conceptualization, collection and review of the literature, interpretation, drafting the manuscript, writing and critical revision. JH and SY were involved in critically revising the manuscript for important intellectual content. WL, XW, HS, TQ and FXC were involved in drafting the manuscript or revising it critically for important intellectual content. HG and ZL were involved in conceptualization, collection and review of the literature. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594, 2008.
2. Rotov J and Bivona TG: Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 17: 637-658, 2017.
3. Arbour KC and Riely GJ: Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review. JAMA 322: 764-774, 2019.
4. Holohan C, Schaebybroeck SV, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 13: 714-726, 2013.
5. Salem A, Asselin MC, Reynen B, Jackson A, Lambin P, West CM, O’Connor JP and Favier-Finn C: Targeting hypoxia to improve non-small cell lung cancer outcome. J Natl Cancer Inst 110, 2018.
6. Fisscher C, Leithner K, Wohlkoeing C, Quehenberger F, Bertsch A, Olschewski H and Hrzenjak A: Panobostatin reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization. Mol Cancer 14: 4, 2015.
7. Navab R, Strumpf D, To C, Pusko E, Kim KS, Park CJ, Hai J, Liu J, Jonkman J, Barczyk M, et al: Integrin α1β1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer. Oncogene 35: 1899-1908, 2016.
8. Su S, Chen J, Yao H, Liu J, Yu S, Lao L, Wang M, Luo M, Xing Y, Chen F, et al: CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness. Cell 172: 841-856.e16, 2018.
9. Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishio Y, Sone S and Yano S: Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Cell 15: 6630-6638, 2009.
10. Radisky DC: Fibroblasts act as co-conspirators for chemotheraphy resistance. Cancer Biol Ther 7: 1348-1349, 2008.
11. Ishii G, Ochiai A and Neri S: Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev 99: 186-196, 2016.
12. Chen WJ, Ho CC, Chang YL, Chen HY, Lin CA, Ling TY, Yu SL, Yuan SS, Chen YJ, Lin CY, et al: Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun 5: 3472, 2014.
13. Leung CS, Yeung TL, Yap KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, et al: Cancer-associated fibroblasts regulate endothelial adhesion protein LRP to promote ovarian cancer chemoresistance. J Clin Invest 128: 589-606, 2017.
14. New J, Arnold L, Ananth M, Alvi S, Thornton M, Werner L, Tawfik O, Dai H, Shnayder Y, Kakarala K, et al: Secretory autophagy in cancer-associated fibroblasts promotes head and neck cancer progression and offers a novel therapeutic target. Cancer Res 77: 6679-6691, 2017.
15. Allauoi R, Bergenhof C, Mohlin S, Hagerling C, Salari K, Werb Z, Anderson RL, Ethier SP, Jirström K, Pahlman S, et al: Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nat Commun 7: 13050, 2016.
16. Sun Y, Wang R, Qiao M, Xu Y, Guan W and Wang L: Cancer associated fibroblasts tailored tumor microenvironment of therapy resistance in gastrointestinal cancers. J Cell Physiol 233: 6359-6369, 2018.
17. von Ahrens D, Bhagat TD, Nagrath D, Maitra A and Verma A: The role of stromal cancer-associated fibroblasts in pancreatic cancer. J Hematol Oncol 10: 76, 2017.
18. Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S, Wang Y, Wang T and Yang Y: Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal IncRNA H19. Theranostics 8: 3932-3948, 2018.
19. Ying L, Zhu Z, Xu Z, He T, Li E, Guo Z, Liu F, Jiang C and Wang Q: Cancer associated fibroblast-derived hepatocyte growth factor inhibits the paclitaxel-induced apoptosis of lung cancer A549 cells by up-regulating the PI3K/Akt and GRP78 signaling on a microfluidic platform. PLoS One 10: e0120953, 2015.
20. Shan T, Chen S, Chen X, Lin WR, Li W, Ma J, Wu T, Ji H, Li Y, Cui X and Yang Y: Prometastatic mechanisms of CAF-mediated EMT regulation in pancreatic cancer cells. Int J Oncol 50: 121-128, 2017.
21. Dai L, Ma L and Wang F: Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells. Int J Oncol 41: 541-550, 2012.
22. Foster DS, Jones RE, Ranson RC, Longaker MT and Norton JA: The evolving relationship of wound healing and tumor stroma. JCI Insight: e99911, 2018.
23. Kojima Y, Acaer A, Eaton EN, Melody KT, Scheel C, Ben-Porath I, Onder TT, Wang ZC, Richardson AL, Weinberg RA and Orimo A: Autocrine TGF-β1 and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 107: 20009-20014, 2010.
24. Louault K, Li R and DeClerck YA: Cancer-associated fibroblasts: Understanding their heterogeneity. Cancers (Basel) 12: 1105, 2020.
25. An Y, Liu F, Chen Y and Yang Q: Crosstalk between cancer-associated fibroblasts and immune cells in cancer. J Cell Mol Med 24: 13-24, 2020.
26. Borriello L, Nakata R, Sheard MA, Fernandez GE, Sposto R, Mulvar J, Blavier L, Shimada H, Asgharzadeh S, Seeger RC and DeClerck YA: Cancer-associated fibroblasts share characteristics and protumorigenic activity with mesenchymal stromal cells. Cancer Res 77: 5142-5157, 2017.
27. Koliaraki V, Pallangyo CK, Greten FR and Kollias G: Mesenchymal cells in colon cancer. Gastroenterology 152: 964-979, 2017.
28. Nair N, Calle AS, Zahra MH, Prieto-Vila M, Oo AKK, Hurley L, Vaidyanath A, Seno A, Masuda J, Ivassaki Y, et al: A cancer stem cell model as the point of origin of cancer-associated fibroblasts in tumor microenvironment. Sci Rep 7: 6838, 2017.
29. Zeisberg EM, Potenta S, Xie L, Zeisberg M and Kalluri R: Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res 67: 10123-10128, 2007.
30. Iwano M, Plieth D, Danoff TM, Xue C, Okada H and Neilson EG: Evidence that fibroblasts derived from epithelium during tissue fibrosis. J Clin Invest 110: 341-350, 2002.
31. McDonald LT, Russell DL, Kelly RR, Xiong Y, Motamarry A, Patel RK, Jones JA, Watson PM, Turner DP, Watson DK, et al: Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment. Neoplasia 17: 434-448, 2015.
32. Gascard P and Tlsty TD: Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy. Genes Dev 30: 1002-1019, 2016.
33. Hosoi A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, Nagai S, Kashi S and Ochiai A: Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: Podoplanin in fibroblast functions for tumor progression. Cancer Res 71: 4769-4779, 2011.
34. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, Hishida T, Nishimura M, Yoshida J, Suzuki K and Ochiai A: Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 123: 1053-1059, 2008.
35. Schoppmann SF, Berghoff A, Dinhof C, Jakes R, Gnant M, Dubsky PS, Jesch B, Heinzl H and Birner P: Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer. Breast Cancer Res Treat 134: 237-244, 2012.
36. Ono S, Ishii G, Nagai K, Takuwa T, Yoshida J, Nishimura M, Hishida T, Aokage K, Fujii S, Ikeda N, Ochiai A, et al: Podoplanin-positive cancer-associated fibroblasts could have prognostic value independent of cancer cell phenotype in stage I invasive squamous cell carcinoma: Usefulness of combining analysis of both cancer cell phenotype and cancer-associated fibroblast phenotype. Chest 143: 963-970, 2013.
CANCER-ASSOCIATED FIBROBLASTS REGULATE NON-SMALL CELL LUNG CANCER DRUG RESISTANCE

7. Schultze AB, Schmidt LH, Heitkötter B, Huss S, Mohr M, Marra A, Hillelan L, Görlich D, Barth PJ, Rekkämper J and Evers G: Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-IIIA NSCLC. Thorac Cancer 11: 242-250, 2020.

8. Hsia LT, Ashley N, Ouaret D, Wang LM, Wilding J and Bodmer WF: Myofibroblasts are distinguished from activated fibroblasts by an expression of collagen and other associated markers. Proc Natl Acad Sci USA 113: E2162-E2171, 2016.

9. Herrera M, Islam AB, Herrera A, Martin P, García V, Silva J, García JM, Salas C, Casal I, de Herreros AG, et al: Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows a prognostic gene expression signature. Clin Cancer Res 19: 5914-5926, 2013.

10. Nurmik M, Ullmann P, Rodriguez F, Haan S and Letellier E: In search of definitions: Cancer-associated fibroblasts and their markers. Int J Cancer 146: 895-905, 2020.

11. Park SY, Kim HM and Koo JS: Differential expression of cancer-associate fibroblast-elastin-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat 149: 727-741, 2015.

12. Patel AK, Vipparthi K, Thaitikonda V, Arun I, Bhattacharjee S, Sharan R, Arun P and Singh S: A subtype of cancer-associated fibroblasts with lower expression of alpha-smooth muscle actin suppresses stemness through BMP4 in oral carcinoma. Oncogenesis 7: 78, 2018.

13. Ohlund D, Elyada E and Tuveson D: Fibroblast heterogeneity in the cancer wound. J Cell Biol 211: 1503-1523, 2014.

14. Bremere PJ and Denzler NC: Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 11: 257-266, 2012.

15. Huber MA, Kraut N, Park JE, Schubert BD, Rettig WJ, Peter RU and Garin-Chouaib F: Pseudomonal activation promotes Differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol 120: 188-188, 2003.

16. Berdiel-Acer M, Sanz-Pamplona R, Calon D, Cuadras D, Berenguerr A, Sanjuan X, Paules MJ, Salazar R, Moreno V, Battle E, et al: Differences between CAFs and their paired NCF from adjacent cancer mucosa reveal functional heterogeneity of CAFs, providing prognostic information. Mol Oncol 8: 1290-1305, 2014.

17. Fearon DT: The carcinoma-associated fibroblast expressing CD200-positive cancer associated fibroblasts and escape from immune surveil- lance. Cancer Immunol Res 2: 187-193, 2014.

18. Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Fearon DT, Hsia LT, Ashley N, Ouaret D, Wang LM, Wilding J and Bodmer WF: Myofibroblasts are distinguished from activated fibroblasts by an expression of collagen and other associated markers. Proc Natl Acad Sci USA 113: E2162-E2171, 2016.

19. Herrera M, Islam AB, Herrera A, Martin P, García V, Silva J, García JM, Salas C, Casal I, de Herreros AG, et al: Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows a prognostic gene expression signature. Clin Cancer Res 19: 5914-5926, 2013.

20. Nurmik M, Ullmann P, Rodriguez F, Haan S and Letellier E: In search of definitions: Cancer-associated fibroblasts and their markers. Int J Cancer 146: 895-905, 2020.

21. Park SY, Kim HM and Koo JS: Differential expression of cancer-associate fibroblast-elastin-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat 149: 727-741, 2015.

22. Patel AK, Vipparthi K, Thaitikonda V, Arun I, Bhattacharjee S, Sharan R, Arun P and Singh S: A subtype of cancer-associated fibroblasts with lower expression of alpha-smooth muscle actin suppresses stemness through BMP4 in oral carcinoma. Oncogenesis 7: 78, 2018.

23. Ohlund D, Elyada E and Tuveson D: Fibroblast heterogeneity in the cancer wound. J Cell Biol 211: 1503-1523, 2014.

24. Bremere PJ and Denzler NC: Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 11: 257-266, 2012.

25. Huber MA, Kraut N, Park JE, Schubert BD, Rettig WJ, Peter RU and Garin-Chouaib F: Pseudomonal activation promotes Differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol 120: 188-188, 2003.
SMO gene amplification and activation of Targeting the myofibroblastic cancer-associated fibroblasts. Nature 367: 645-648, 1994.

77. Leon G, MacDonagh L, Finn SP, Cuffe S and Barr MP: Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. Pharmacol Ther 158: 71-90, 2016.

78. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ and Lee EY: Cancer stem cells contribute to cisplatin resistance in 533-mediated mouse mammary tumors. Cancer Res 68: 3243-3250, 2008.

79. Schöning JP, Monteiro M and Gu W: Drug resistance and cancer stem cells: The shared but distinct roles of hypoxia-inducible factors HIF1α and HIF2α. Curr Exp Pharmacol Physiol 44: 151-164, 2017.

80. Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L and Li J: Mammalian diabetic efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett 370: 153-164, 2016.

81. Kinugasa Y, Matsui T and Takakura N: CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells 32: 145-156, 2014.

82. Najafi M, Farhood B and Mortezaee K: Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem 115: 2019-2030, 2014.

83. Keeratichamroen S, Lirdprapamongkol K and Svasti J: Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells. Oncol Rep 39: 1765-1774, 2018.

84. De Rosa V, Iommielli F, Monti M, Fonti R, Votta G, Stoppelli MP and Del Vecchio S: Reversal of warburg effect and reactionivation of phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res 21: 5110-5120, 2015.

85. Iderezor T, Kellen J, Osude C, Singh S, Woodman JA, Garcia C and Puri N: Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC. Biochem Biophys Res Commun 496: 380-387, 2018.

86. Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J, Chen B, Xie B and Chen X: Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. Neuro Oncol 14: 1227-1238, 2012.

87. Raju S, Joseph R and Sehgal S: Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther 7: 63-75, 2018.

88. Kloten V, Lamigpanno R, Krahn T and Schlange T: Circulating tumor Cell PD-L1 expression as biomarker for therapeutic efficacy 1201-1202: biomarker in NSCLC. Ann Oncol 26: 1268-1281, 2015.

89. Pu X, Wu L, Su D, Mao W and Fang B: Immunotherapy for non-small lung cancers: Biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer 18: 1082, 2018.

90. Salmon H, Franciszkiewicz K, Dumonte D, Dieu-Nosjean MC, Vaillant C, Trautmann A and Chauvin-Delalande F: Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122: 899-910, 2012.

91. Ono Y, Fujisawa Y, Akashi M, Hayashi T, Ito Y, Ito Y, Kato T, Minagawa J, Ito Y, Watanabe T and Kato T: Progression of NSCLC by CD44v6 expression. Int J Oncol 60: 16-22, 2021.

92. De Rosa V, Iommielli F, Monti M, Stoppelli MP and Del Vecchio S: Reversal of warburg effect and reactivation of phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res 21: 5110-5120, 2015.

93. Iderezor T, Kellen J, Osude C, Singh S, Woodman JA, Garcia C and Puri N: Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC. Biochem Biophys Res Commun 496: 380-387, 2018.

94. Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J, Chen B, Xie B and Chen X: Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. Neuro Oncol 14: 1227-1238, 2012.

95. Raju S, Joseph R and Sehgal S: Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther 7: 63-75, 2018.

96. Kloten V, Lamigpanno R, Krahn T and Schlange T: Circulating tumor Cell PD-L1 expression as biomarker for therapeutic efficacy 1201-1202: biomarker in NSCLC. Ann Oncol 26: 1268-1281, 2015.

97. Pu X, Wu L, Su D, Mao W and Fang B: Immunotherapy for non-small lung cancers: Biomarkers for predicting responses and strategies to overcome resistance. BMC Cancer 18: 1082, 2018.

98. Salmon H, Franciszkiewicz K, Dumonte D, Dieu-Nosjean MC, Vaillant C, Trautmann A and Chauvin-Delalande F: Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 122: 899-910, 2012.

99. Ono Y, Fujisawa Y, Akashi M, Hayashi T, Ito Y, Ito Y, Kato T, Minagawa J, Ito Y, Watanabe T and Kato T: Progression of NSCLC by CD44v6 expression. Int J Oncol 60: 16-22, 2021.

100. De Rosa V, Iommielli F, Monti M, Stoppelli MP and Del Vecchio S: Reversal of warburg effect and reactivation of phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer. Clin Cancer Res 21: 5110-5120, 2015.

101. Iderezor T, Kellen J, Osude C, Singh S, Woodman JA, Garcia C and Puri N: Comparison of EMT mediated tyrosine kinase inhibitor resistance in NSCLC. Biochem Biophys Res Commun 496: 380-387, 2018.

102. Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J, Chen B, Xie B and Zhang WM: Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer cells. Oncol Lett 6: 4433-4435, 2015.

103. Chen C, Shi YS, Kim C, Chen SJ, Lee C, Kim SY, Choy YB and Kim J: Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition. Oncol Targets Ther 8: 3665-3678, 2015.

104. Delia Corte RM, Bellavite C, vicidomini G, vitagliano D, Malapelle U, Accardo M, fabozzi A, Fiorelli A, pasano M, papicco F, et al.: SMO gene amplification and activation of the hedgehog pathway as novel mechanisms of resistance to anti-epidermal growth factor receptor drugs in human lung cancer cells. Clin Cancer Res 21: 4606-4619, 2015.

105. Murakami A, Takahashi F, nurwidyansah K, Ichihara k, Hashimoto M, Nara T, Kato M, Tajima K, Shimada N, et al.: Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor. PLoS One 4, 2009.

106. Petrova V, Annichiarico-petrizelli M, Melino G and Amelio I: The hypoxic tumor microenvironment. Oncogenesis 7: 10, 2018.
115. Duan S, Tsai Y, Keng P, Chen Y, Lee SO and Chen Y: IL-6 signaling contributes to cisplatin resistance in non-small cell lung cancer via the up-regulation of anti-apoptotic and DNA repair associated molecules. Oncotarget 6: 27651-27660, 2015.
116. Wang L, Li X, Ren Y, Geng H, Zhang Q, Cao L, Meng Z, Wu X, Xu M and Xu K: Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells. Cancer Sci 110: 1609-1620, 2019.
117. Wei JR, Dong J and Li L: Cancer-associated fibroblasts-derived gamma-glutamyltransferase 5 promotes tumor growth and drug resistance in lung adenocarcinoma. Aging (Albany NY) 12: 13220-13233, 2020.
118. Tao L, Huang G, Wang R, Pan Y, He Z, Chu X, Song H and Chen L: Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway. Sci Rep 6: 38408, 2016.
119. Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, et al: JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol Cancer Ther 16: 2234-2245, 2017.
120. Foster JG, Wong SC and Sharp TV: The hypoxic tumor microenvironment: Driving the tumorigenesis of non-small-cell lung cancer. Future Oncol 10: 2659-2674, 2014.
121. Rebelo SP, Pinto C, Martins TR, Harrer N, Estrada MF, Loza-Alvarez P, Cabeçadas J, Alves PM, Gualda EI, Sommergruber W and Brito C: 3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment. Biomaterials 163: 185-197, 2018.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.